Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2-breast cancer: results from two prospective trials

被引：20

作者：

Dieci, M. V. ^{[1
,2
]}

Frassoldati, A. ^{[3
]}

Generali, D. ^{[4
,5
]}

Bisagni, G. ^{[6
]}

Piacentini, F. ^{[7
,8
]}

Cavanna, L. ^{[9
]}

Cagossi, K. ^{[10
]}

Puglisi, F. ^{[11
,12
,13
]}

Michelotti, A. ^{[14
]}

Berardi, R. ^{[14
]}

Banna, G. ^{[15
]}

Goubar, A. ^{[16
]}

Ficarra, G. ^{[17
]}

Griguolo, G. ^{[1
,2
]}

Conte, Pierfranco ^{[1
,2
]}

Guarneri, V. ^{[1
,2
]}

机构：

[1] Univ Padua, Dept Surg Oncol & Gastroenterol, Via Giustiniani 2, I-35128 Padua, Italy

[2] Ist Oncol Veneto IRCCS, Div Med Oncol 2, Via Gattamelata 64, I-35128 Padua, Italy

[3] S Anna Univ Hosp, Div Clin Oncol, Via Moro 8, I-44100 Ferrara, Italy

[4] Breast UnitASST Cremona, Viale Concordia 1, I-26100 Cremona, Italy

[5] Univ Trieste, Dept Med Surg & Hlth Sci, Piazza Ospitale 1, I-34129 Trieste, Italy

[6] Azienda Osped ASMN, Div Med Oncol, IRCSS, Viale Umberto 1 50, I-42123 Reggio Emilia, Italy

[7] Univ Modena & Reggio Emilia, Dept Med & Surg Sci Mother Child & Adult, Modena, Italy

[8] Modena Univ Hosp, Div Med Oncol, Via Pozzo 71, I-41124 Modena, Italy

[9] Guglielmo da Saliceto Hosp, Div Oncol, Via Taverna 49, I-29121 Piacenza, Italy

[10] B Ramazzini Hosp, Div Med Oncol, Via Molinari 2, I-41012 Carpi, Italy

[11] Univ Udine, Dept Med & Biol Sci, Udine, Italy

[12] Univ Hosp Udine, Dept Oncol, Piazzale Santa Maria Misericordia 15, I-33010 Udine, Italy

[13] Univ Pisana, Santa Chiara Hosp, UO Oncol Med 1, Azienda Osped, Via Roma 67, I-56126 Pisa, Italy

[14] Univ Politecn Marche, Div Med Oncol, Osped Riuniti Umberto 1, Via Conca 71, I-60126 Ancona, Italy

[15] Cannizzaro Hosp, Div Med Oncol, Via Messina 829, I-95126 Catania, Italy

[16] ICR Clin Trials & Stat Unit, 15 Cotswold Rd, Sutton SM2 5NG, Surrey, England

[17] Modena Univ Hosp, Div Pathol, Via Pozzo 71, I-41124 Modena, Italy

来源：

BREAST CANCER RESEARCH AND TREATMENT | 2017年 / 163卷 / 02期

关键词：

Tumor-infiltrating lymphocytes; Neoadjuvant; Chemotherapy; Endocrine therapy; Ki67; POSITIVE BREAST-CANCER; PREDICTIVE-VALUE; SUBTYPES;

D O I：

10.1007/s10549-017-4191-y

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The aim was to evaluate the role of tumor-infiltrating lymphocytes (TIL) in predicting molecular response after preoperative endocrine or cytotoxic treatment for HR+/HER2- patients who do not achieve a pathological complete response. Stromal (Str) TIL were centrally evaluated on samples from diagnostic core-biopsies of HR+/HER2- patients included in two prospective randomized trials: the LETLOB trial (neoadjuvant endocrine-based treatment) and the GIOB trial (neoadjuvant chemotherapy-based treatment). Pre- and post-treatment Ki67 was centrally assessed. StrTIL were evaluable in 111 cases (n = 73 from the LETLOB trial and n = 38 from the GIOB trial). Median StrTIL was 2%. Patients with high StrTIL (StrTIL aeyen10%, n = 28) had more frequently breast cancer of ductal histology (p = 0.02), high grade (p = 0.049), and high Ki67 (p = 0.02). After neoadjuvant endocrine treatment (LETLOB cohort), a significant Ki67 suppression (p 0.01) from pre- to post-treatment was observed in both the low and high StrTIL groups. High StrTIL patients achieve more frequently a relative Ki67 suppression aeyen50% from baseline as compared to low StrTIL patients (55 vs. 35%, p non significant). After neoadjuvant chemotherapy (GIOB cohort), a significant Ki67 suppression was observed only for low StrTIL patients (Wilcoxon p = 0.001) and not in the high StrTIL group (p = 0.612). In this cohort, the rate of patients achieving a relative Ki67 suppression aeyen50% from baseline was significantly higher in the high vs low StrTIL group (64 vs. 10%, p = 0.003). Geometric mean Ki67 suppression was evaluated in each cohort according to StrTIL: the lowest value (-41%) was observed for high StrTIL cases treated with chemotherapy. This hypothesis-generating study suggests that in HR+/HER2- breast cancer StrTIL at baseline may influence the achievement of a molecular response after neoadjuvant treatment. Further evaluation in large studies is needed, and interaction with the type of treatment warrants to be explored.

引用

页码：295 / 302

页数：8

共 20 条

[1]

[Anonymous], 2016, R LANGUAGE ENV STAT

[2] Neoadjuvant hormonal therapy for endocrine sensitive breast cancer: A systematic review [J].

Charehbili, A. ;

Fontein, D. B. Y. ;

Kroep, J. R. ;

Liefers, G. J. ;

Mieog, J. S. D. ;

Nortier, J. W. R. ;

van de Velde, C. J. H. .

CANCER TREATMENT REVIEWS, 2014, 40 (01) :86-92

[3] Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis [J].

Cortazar, Patricia ;

Zhang, Lijun ;

Untch, Michael ;

Mehta, Keyur ;

Costantino, Joseph P. ;

Wolmark, Norman ;

Bonnefoi, Herve ;

Cameron, David ;

Gianni, Luca ;

Valagussa, Pinuccia ;

Swain, Sandra M. ;

Prowell, Tatiana ;

Loibl, Sibylle ;

Wickerham, D. Lawrence ;

Bogaerts, Jan ;

Baselga, Jose ;

Perou, Charles ;

Blumenthal, Gideon ;

Blohmer, Jens ;

Mamounas, Eleftherios P. ;

Bergh, Jonas ;

Semiglazov, Vladimir ;

Justice, Robert ;

Eidtmann, Holger ;

Paik, Soonmyung ;

Piccart, Martine ;

Sridhara, Rajeshwari ;

Fasching, Peter A. ;

Slaets, Leen ;

Tang, Shenghui ;

Gerber, Bernd ;

Geyer, Charles E., Jr. ;

Pazdur, Richard ;

Ditsch, Nina ;

Rastogi, Priya ;

Eiermann, Wolfgang ;

von Minckwitz, Gunter .

LANCET, 2014, 384 (9938) :164-172

[4]

Denkert C, 2016, 39 SAN ANT BREAST CA

[5] Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer [J].

Denkert, Carsten ;

Loibl, Sibylle ;

Noske, Aurelia ;

Roller, Marc ;

Mueller, Berit Maria ;

Komor, Martina ;

Budczies, Jan ;

Darb-Esfahani, Silvia ;

Kronenwett, Ralf ;

Hanusch, Claus ;

von Toerne, Christian ;

Weichert, Wilko ;

Engels, Knut ;

Solbach, Christine ;

Schrader, Iris ;

Dietel, Manfred ;

von Minckwitz, Gunter .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (01) :105-113

[6] Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study (vol 25, pg 611, 2015) [J].

Dieci, M. V. ;

Criscitiello, C. ;

Goubar, A. ;

Viale, G. ;

Conte, P. ;

Guarneri, V. ;

Ficarra, G. ;

Mathieu, M. C. ;

Delaloge, S. ;

Curigliano, G. ;

Andre, F. .

ANNALS OF ONCOLOGY, 2015, 26 (07) :1518-1518

[7] The immune system and hormone-receptor positive breast cancer: Is it really a dead end? [J].

Dieci, Maria Vittoria ;

Griguolo, Gaia ;

Miglietta, Federica ;

Guarneri, Valentina .

CANCER TREATMENT REVIEWS, 2016, 46 :9-19

[8] Molecular Profiling of Aromatase Inhibitor-Treated Postmenopausal Breast Tumors Identifies Immune-Related Correlates of Resistance [J].

Dunbier, Anita K. ;

Ghazoui, Zara ;

Anderson, Helen ;

Salter, Janine ;

Nerurkar, Ashutosh ;

Osin, Peter ;

A'hern, Roger ;

Miller, William R. ;

Smith, Ian E. ;

Dowsett, Mitch .

CLINICAL CANCER RESEARCH, 2013, 19 (10) :2775-2786

[9] Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics [J].

Ellis, Matthew J. ;

Tao, Yu ;

Luo, Jingqin ;

A'Hern, Roger ;

Evans, Dean B. ;

Bhatnagar, Ajay S. ;

Ross, Hilary A. Chaudri ;

von Kameke, Alexander ;

Miller, William R. ;

Smith, Ian ;

Eiermann, Wolfgang ;

Dowsett, Mitch .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (19) :1380-1388

[10] Immunomodulation of FOXP3+ Regulatory T Cells by the Aromatase Inhibitor Letrozole in Breast Cancer Patients [J].

Generali, Daniele ;

Bates, Gaynor ;

Berruti, Alfredo ;

Brizzi, Maria P. ;

Campo, Leticia ;

Bonardi, Simone ;

Bersiga, Alessandra ;

Allevi, Giovanni ;

Milani, Manuela ;

Aguggini, Sergio ;

Dogliotti, Luigi ;

Banham, Alison H. ;

Harris, Adrian L. ;

Bottini, Alberto ;

Fox, Stephen B. .

CLINICAL CANCER RESEARCH, 2009, 15 (03) :1046-1051

← 1 2 →